In 2001, the US Food and Drug Administration approved recombinant tissue plasminogen activator (alteplase, Cathflo Activase) to reestablish patency of central catheters occluded, presumably, by a ...

Purpose. The efficacy and safety of i.v. alteplase up to 4.5 hours after acute ischemic stroke (AIS) onset were evaluated. Summary. Stroke is the leading cause of disability in the elderly, and i.v.

A three month treatment with 300 mg IV aspirin does not improve the functional outcome of alteplase-treated acute ischemic stroke patients. However, the risk of developing SICH and SAEs is enhanced.

Stroke patients treated with intravenous alteplase (Activase) did not have more intracranial hemorrhages if they had recently taken non-vitamin K antagonist oral anticoagulants (NOACs), according to ...

Endovascular thrombectomy alone was noninferior to thrombectomy plus thrombolysis with alteplase in terms of functional outcome for patients with large-vessel acute ischemic stroke in a new Chinese ...

The full CMI on the next page has more details. If you are worried about being given this medicine, speak to your doctor. Actilyse Cathflo contains the active ingredient alteplase. It belongs in the ...

DALLAS -- Dual antiplatelet therapy (DAPT) proved non-inferior to IV alteplase in Chinese patients with minor non-disabling stroke, a researcher reported. In the ARAMIS trial of patients with acute ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — Intracoronary alteplase administered during primary PCI for STEMI does not reduce microvascular ...